Global Coalition for Adaptive Research (GCAR), a coalition comprised of some of the world’s foremost clinical, translational and basic science investigators has announced its official launch. As its first priority, GCAR will serve as the official sponsor of GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM)

The All.Can patient survey enables brain tumour patients to give their views on what needs to improve or change in the delivery of care in their countries in order to achieve better outcomes for those affected by cancer. The survey is currently live in the UK and will soon be launching across many countries in Europe as well as Canada and Australia.

A study published in Cell Reports highlights findings identifying specific predictive biomarkers that could help assess the level of risk for recurrence in patients with malignant glioma.

A team led by researchers from Uppsala University (Sweden), in collaboration with a number of American colleagues, has found that by combining two kinds of medicines to treat medulloblastoma, they may have discovered an Achilles' heel for the most common type of malignant childhood brain tumour.

Taking a biopsy of a brain tumour is a complicated and invasive surgical process, but a recent study published in Scientific Reports has demonstrated a technique that allows tumour biomarkers to be detected through a simple blood test, potentially eliminating the need for surgical biopsy.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.